AbCellera Biologics, Inc. (ABCL)
| Market Cap | 13.03B |
| Revenue (ttm) | 28.45M |
| Net Income (ttm) | 277,000 |
| Shares Out | 266.32M |
| EPS (ttm) | 0.00 |
| PE Ratio | 47,187.94 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $49.08 |
| Previous Close | $44.41 |
| Change ($) | 4.67 |
| Change (%) | 10.52% |
| Day's Open | 44.94 |
| Day's Range | 44.94 - 49.32 |
| Day's Volume | 1,252,178 |
| 52-Week Range | 36.59 - 58.90 |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology.
AbCellera CEO on effectiveness of Covid-19 anitbody treatment
AbCellera Biologics CEO Carl Hansen joins 'Closing Bell' to discuss the company's partnership with Eli Lilly in developing monoclonal antibody treatment and the company's Covid-19 treatments.
Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Pi...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share.
AbCellera is continuing forward with its IPO plans and has provided new details in a filing with the SEC that investors will want to know. The post ABCL Stock IPO: When Does AbCellera Go Public?
AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide.
AbCellera Biologics Inc. ABCL, said Monday that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $...
AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19.
Peter Thiel-backed biotech developer AbCellera Biologics Inc, which has partnered with Eli Lilly for its COVID-19 antibody drug, on Friday filed for an initial public offering on the Nasdaq.
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, filed on Friday with the SEC to raise up to $200 million in an initial public offering.
AbCellera Biologics, Inc. has filed to go public with an IPO on the NASDAQ.
About ABCL
AbCellera Biologics develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquarter... [Read more...]
| Industry Biotechnology | IPO Date Dec 11, 2020 |
| CEO Carl L. G. Hansen | Employees 174 |
| Stock Exchange NASDAQ | Ticker Symbol ABCL |
Analyst Forecasts
The average 12-month stock price forecast for ABCL is 51.40, which is an increase of 4.73% from the latest price.